{"id":"NCT01007942","sponsor":"Novartis Pharmaceuticals","briefTitle":"Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer","officialTitle":"A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10","primaryCompletion":"2015-06","completion":"2015-06","firstPosted":"2009-11-04","resultsPosted":"2017-04-05","lastUpdate":"2017-04-05"},"enrollment":569,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["HER2/Neu Over-expressing Locally Advanced Breast Cancer","Metastatic Breast Cancer"],"interventions":[{"type":"DRUG","name":"everolimus","otherNames":["RAD001"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"vinorelbine","otherNames":[]},{"type":"DRUG","name":"trastuzumab","otherNames":[]}],"arms":[{"label":"Everolimus + vinorelbine + trastuzumab","type":"EXPERIMENTAL"},{"label":"placebo + vinorelbine + trastuzumab","type":"PLACEBO_COMPARATOR"}],"summary":"This phase III, double-blind, placebo-controlled multinational study will assess the combination everolimus, vinorelbine, and trastuzumab compared to the combination vinorelbine and trastuzumab with respect to progressive-free survival and over survival in HER2/neu positive women with locally advanced or metastatic breast cancer who are resistant to trastuzumab and have been pre-treated with a taxane.","primaryOutcome":{"measure":"Progressive-free Survival (PFS) Per Investigator Assessment","timeFrame":"Every 6 weeks until disease progression or death which ever occurred first up to about 41 months","effectByArm":[{"arm":"Everolimus + Vinorelbine + Trastuzumab","deltaMin":7,"sd":null},{"arm":"Placebo + Vinorelbine + Trastuzumab","deltaMin":5.78,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0067"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":10},"locations":{"siteCount":161,"countries":["United States","Argentina","Australia","Belgium","China","Czechia","France","Germany","Greece","Hungary","Israel","Italy","Japan","Mexico","Poland","Singapore","Slovakia","Spain","Thailand","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["24742739"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":122,"n":280},"commonTop":["Neutropenia","Stomatitis","Fatigue","Leukopenia","Anaemia"]}}